Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Methylprednisolone for Inflammatory Response in CABG
NCT07101367Phase 2Not yet recruiting
- Sponsor
- Ain Shams University
- Start
- Sep 2025
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dexmedetomidine, methylprednisolone injection in Systemic Inflammatory Response Syndrome (SIRS), sponsored by Ain Shams University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
dexmedetomidinemethylprednisolone injection
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT07101367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101367.